The inhibition of ANRIL could restrain the cell proliferation, invasion, migration of pancreatic cancer, and reduce chemotherapy resistance to gemcitabine through sponging miR-181a to target HMGB1-induced cell autophagy. Here, HMGB1 is linked to familial pancreatic carcinoma.